Melanocortin signalling in leucocyte subsets elicits anti-inflammatory and immune tolerance inducing effects in animal experimental inflammation. In man, however, the effects of melanocortin signalling in inflammatory conditions have scarcely been examined. We explored the differential reactions of melanocortin 1-5 receptors (MC1-5R) gene expressions in pathogenetic leucocyte subsets in rheumatoid arthritis (RA) to treatment with TNF-a inhibitor adalimumab. Seven patients with active RA donated blood at start and at 3-month treatment. CD4 + T helper (h) lymphocytes (ly), CD8 + T cytotoxic (c) ly, CD19 + B ly and CD14 + monocytes were isolated, using immunomagnetic beads, total RNA extracted and reverse transcription quantitative polymerase chain reaction (RT-qPCR) performed. Fold changes in MC1-5R, Th1-, inflammatory-and regulatory cytokine gene expressions were assessed for correlation. Six patients responded to adalimumab treatment, while one patient was non-responder. In all lymphocyte subtypes, MC1-5R gene expressions decreased in responders and increased in the non-responder. 
Abstract
Melanocortin signalling in leucocyte subsets elicits anti-inflammatory and immune tolerance inducing effects in animal experimental inflammation. In man, however, the effects of melanocortin signalling in inflammatory conditions have scarcely been examined. We explored the differential reactions of melanocortin 1-5 receptors (MC1-5R) gene expressions in pathogenetic leucocyte subsets in rheumatoid arthritis (RA) to treatment with TNF-a inhibitor adalimumab. Seven patients with active RA donated blood at start and at 3-month treatment. CD4 + T helper (h) lymphocytes (ly), CD8 + T cytotoxic (c) ly, CD19 + B ly and CD14 + monocytes were isolated, using immunomagnetic beads, total RNA extracted and reverse transcription quantitative polymerase chain reaction (RT-qPCR) performed. Fold changes in MC1-5R, Th1-, inflammatory-and regulatory cytokine gene expressions were assessed for correlation. Six patients responded to adalimumab treatment, while one patient was non-responder. In all lymphocyte subtypes, MC1-5R gene expressions decreased in responders and increased in the non-responder. In responders, decrease in MC2R, MC3R and MC4R gene expressions in CD8 + Tc and CD19 + B ly was significant. Fold change in MC1-5R and IFNc gene expressions correlated significantly in CD8 + Tc ly, while fold change in MC1R, MC3R and MC5R and IL1b gene expressions correlated significantly in CD4 + Th ly. Our results show regulation of MC2R, MC3R and MC4R gene expressions in CD8 + Tc ly and CD19
Introduction
Rheumatoid arthritis (RA) is a debilitating autoimmune disease, which affects about 1% of the population in western countries. In RA, auto-reactive T cells expand and migrate into the synovium, where they induce inflammation, leading to cartilage damage and bone resorption. Although biologic disease modifying agents (bDMARDs), such as monoclonal antibodies against TNF-a, have improved disease outcome, around 40% of the patients do not react satisfactorily to treatment [1] . The five melanocortin receptors, MC1-5R, which are seven-helix, transmembrane, G-protein coupled, were discovered in the 1990s [2, 3] . At first, MC1R was demonstrated in melanocytes, controlling pigmentation, MC2R in the adrenal cortex being the adrenocorticotropin (ACTH) receptor per se, MC3R and MC4R in the hypothalamus, regulating food intake and libido. MC5R was found in exocrine glands, controlling secretion. The ligands of the MCRs are the melanocortins derived from pro-opio-melanocortin (POMC), which is cleaved into a-, b-and c-melanocyte stimulating hormone (MSH) and ACTH [4] . While MC2R only binds ACTH, all other MCRs bind both ACTH and MSHs [5] . The MCRs exhibit specific affinity for the different melanocortins [4] and may thus be targeted differentially.
We have previously demonstrated MC1R protein expression in human CD8 + cytotoxic (c) T ly and CD19 B ly [6] . Furthermore, we found MC1R, MC2R, MC3R and MC5R gene expression in CD4 + T helper (h), CD8 + T cytotoxic (c) ly, CD19 + B ly and CD14 + monocytes [7] . Others have reported a wide spectrum of anti-inflammatory and immune modulating actions of melanocortin signalling in animal experimental inflammatory conditions such as urate crystal-induced arthritis [8] , experimental autoimmune uveoretinitis [9] and contact hypersensitivity dermatitis [10] . Melanocortin signalling primarily inhibits nuclear translocation of transcription factor nuclear factor kappa B (NFjB), leading to downregulation of the synthesis of several inflammatory mediators, for example inflammatory cytokine TNF-a, adhesion molecules and nitric oxide [11] . Interestingly, melanocortin signalling may even convert CD4 + Th effector ly into CD4 + CD25 + regulatory T ly (Tregs) [9] and transform CD8 + Tc ly reactivity into tolerance in murine contact dermatitis [10] .
The pathogenesis in RA has not yet been fully elucidated. A significant disease driving role of the Th1 response is, however, well established. Both CD4 + Th ly and CD8 + Tc ly produce the disease driving Th1 response signature cytokine IFN-c in significant amounts in RA [12] [13] [14] . Evidence has accumulated that the autoimmune reaction in RA might be triggered by the encounter of T cells with proteins modified by citrullination [15] . Recently, ACPA-specific intravenous immunoglobulin treatment was found to relieve collagen-induced ACPApositive arthritis in mice, pointing at a causative role for ACPA in arthritis [16] . Hypothetically, melanocortin signalling might induce tolerance to citrullinated protein, as melanocortin signalling induces immune tolerance to innocuous antigens in murine autoimmune uveoretinitis [9] , encephalomyelitis [17] and contact dermatitis [10] .
In various cells and tissues, gene expression of MC1-5R is stimulated by melanocortin signalling. The synthesis of the melanocortins is in turn stimulated by inflammatory cytokines [18] [19] [20] . Thus, changes in MCR gene expressions during adalimumab treatment would point at actual melanocortin signalling. To explore the opportunities for MCR targeting in RA, we searched for evidence of responsiveness of the melanocortin system in pathogenetic leucocyte subsets. To this end, we measured fold changes in MC1-5R gene expressions due to adalimumab treatment. Moreover, we correlated changes in MC1-5R and Th1, inflammatory and regulatory cytokine gene expressions to evaluate the role of the melanocortin system in RA.
Responsiveness could open the door to in vivo or in vitro treatment of immune response directing lymphocyte subsets with MCR selective melanocortin analogues in man.
Patients and methods
Ethics, consent and permissions. The Ethics Committee of Northern Jutland, Denmark, approved the study (N-20100060). All patients gave their informed consent, orally and in writing.
Patients At the point of inclusion, three patients medicated with 10 mg prednisolone/day, four patients with methotrexate, mean dose 18.75 mg/week (17.5-25 mg/week), another two patients with sulfasalazine, mean dose 2250 mg/day and three patients with leflunomide 20 mg/day. Three patients were current smokers, with a mean of 10 packyears. All seven patients had normal body mass index and no comorbidity. The patients were carefully instructed in the use of adalimumab injection pens 40 mg/dose (Humira â ) (AbbVie, North Chicago, IL, USA), which were handed to the patients at our clinic every month. The patients accounted for their use.
Electronic patient self-reported outcome (DANBIO). Patients reported pain-fatigue-and patient 0 s global on a 100-mm visual analogue scale (VAS), as well as answered the health assessment questionnaire (HAQ) electronically before adalimumab was started (at baseline) and at 3-month follow-up of treatment. Recordings were saved in DANBIO, a national electronic data register, aimed to survey bDMARD-treated patients with RA.
Methods. Isolation of peripheral mononuclear blood leucocytes peripheral blood mononuclear cells (PBMC). Peripheral blood samples were donated by the seven patients with RA at baseline and at 3-month follow-up of adalimumab treatment. For lymphocyte isolation, whole blood was diluted 1:1 with Tris-buffered Hank's salt solution, pH 7.2, and subjected to Ficoll-isopaque (Lymphoprep, Nycomed, Oslo, Norway) gradient centrifugation. The interface, containing PBMC, was collected. Subpopulations of PBMC were isolated by Mab coupled to Dynabeads (Dynal, Oslo, Norway). In brief, Dynabeads coated with anti-CD4, anti-CD8, anti-CD14 or anti-CD19 mAbs were incubated with the isolated PBMC for 2 h with end-to-end rotation at 4°C. The cell fraction bound to the beads was washed five times with PBS and used for RNA extraction.
Monoclonal antibodies. All the monoclonal antibodies used herein were purchased from DAKO A/S (Glostrup, Denmark). Specificities of the monoclonal antibodies: CD4, CD8, CD19 and their negative isotype control were all IgG1 isotype and derived from Mab/clone MT310, DK25, HD37 and DAK-G01, respectively. CD14 and its negative isotype control were of IgG2a isotype derived from Mab/ clone TUK4 and DAK-G05, respectively.
Total RNA extraction. Lysates from CD4 + , CD8 + , CD14
+ and CD19 + cells (>95% purity) were used to extract total RNA by the acid guanidinium thiocyanatephenol-chloroform method.
Quantitative reverse transcription polymerase chain reaction (RT-qPCR). Custom gene expression analysis according to the MIQE guidelines [22] However, in silico specificity screen by BLAST is impossible because the producer does not disclose the primer/ probe sequences. We performed uniformly multiplexed tests with cDNA input equal to 5 ng of total RNA in 96-well plates and reaction volume 20 ll/well using 29 Universal Master Mix on a 7900HT instrument (all from Life Thermo Fisher Scientific Inc.). Each plate included both the no template control (NTC) and the PMA/ ionomycin-stimulated PBMC (sPBMC) as an internal positive control. The data were computed by the ddC t method resulting in relative quantities (RQ) comparative to a reference expression level in sPBMC equal to 1. Foldchange value is the result of division of RQ after therapy by RQ before therapy. Statistics. Results are reported as median and IQR. Wilcoxon 0 s matched-pairs signed rank test for continuous data was used to evaluate differences between receptor and cytokine mRNA levels as well as disease activity variables at baseline and 3-month follow-up of treatment. The patients served as their own controls. This set-up is advantageous as it eliminates confounding factors. Correlation analyses were performed using the non-parametric Spearman rank correlation test. All P values were twosided; P < 0.05 was considered significant. All analyses .......................................................................................................................................................... A 47-year-old male patient with RA since half a year and DAS28 (CRP) 4.4, highly positive RF 145 kIU/l (<10 kIU/ l) and highly positive ACPA >600 AE/l (<14 AE/l) at inclusion, did not respond to adalimumab, despite combination with 25 mg methotrexate s.c. a week. At 3-month follow-up of adalimumab treatment, the patient had developed rheumatoid nodules and had six tender and swollen joints. The patient was not smoking.
MC1-5R gene expressions in pathogenetic leucocyte subsets before and during TNF-aI in responding and non-responding patients with RA MC1-5R gene expressions decreased significantly in leucocyte subsets of adaptive immunity in patients with RA responding to adalimumab and increased in the non-responding patient MC1-5R gene expressions were downregulated in CD4 + Th ly, CD8 + Tc ly and CD19 + B ly at 3-month follow-up in patients with RA responding to adalimumab. MC2R, MC3R and MC4R gene expressions were significantly downregulated in CD8 + Tc ly and CD19 + B ly. Furthermore, MC5R gene expression was significantly downregulated in CD19 + B ly (Fig. 1 ). In the patient with RA not responding to adalimumab, MC1-5R gene expressions were upregulated in CD4 + Th ly, CD8 + Tc ly and CD19 + B ly, at 3 months follow-up of treatment.
MC1-5R gene expressions decreased in cells of innate immunity in patients with RA responding as well as not responding to adalimumab

MC1-5R gene expressions were insignificantly downregulated in CD14
+ monocytes at 3 months follow-up in patients with RA responding to adalimumab.
In the patient with RA not responding to adalimumab, MC1-5R gene expressions were slightly downregulated in CD14
+ monocytes, at 3-month follow-up of treatment.
Th1-, inflammatory-and regulatory cytokine gene expressions in pathogenetic leucocyte subsets before and during TNF-aI in responding and non-responding patients with RA Th1 cytokine gene expressions decreased in leucocyte subsets of adaptive immunity in patients with RA responding to adalimumab and increased in the non-responding patient IFN-c and TNF-b gene expressions were downregulated in CD4 + Th ly, CD8 + Tc ly and CD19 + B ly at 3-month follow-up in patients with RA responding to adalimumab (Fig. 1) . TNF-b gene expression was significantly downregulated in CD8 + Tc ly and tended to be significantly downregulated in CD4 + Th ly (P = 0.06). In the patient with RA not responding to adalimumab, IFN-c and TNF-b gene expressions were upregulated in CD4 + Th ly, CD8 + Tc ly and CD19 + B ly at 3-month follow-up of treatment.
Inflammatory cytokine gene expressions decreased in leucocyte subsets of adaptive immunity in patients with RA responding to adalimumab and increased in the non-responding patient IL-1b and TNF-a gene expressions were downregulated, however insignificantly, in CD4 + Th ly, CD8 + Tc ly and CD19 + B ly at 3-month follow-up in patients with RA responding to adalimumab.
In the patient with RA not responding to adalimumab, IL-1b and TNF-a gene expressions increased in CD4 + Th ly, CD8 + Tc ly and CD19 + B ly at 3-month follow-up of treatment.
Inflammatory cytokine gene expressions decreased in cells of innate immunity in patients with RA responding to adalimumab and increased in the non-responding patient IL-1b and TNF-a gene expressions were downregulated in CD14 + monocytes at 3-month follow-up in patients with RA responding to adalimumab. Fall in IL-1b gene expression almost reached significance (P = 0.06).
In the patient with RA not responding to adalimumab, IL-1b and TNF-a gene expressions increased in CD14 Regulatory cytokine gene expressions in leucocyte subsets of adaptive immunity in patients with RA responding to adalimumab and in the non-responding patient IL-10 and TGF-b gene expressions were downregulated in CD4 + Th ly and CD8 + Tc ly at 3-month follow-up in patients with RA responding to adalimumab. Moreover, IL-10 gene expression was downregulated and TGF-b gene expression was upregulated in CD19 + B ly. In CD4 + Th ly, the downregulation of IL-10 gene expression was significant, while the downregulation of TGF-b gene expression tended to be significant (P = 0.06).
In the patient with RA not responding to adalimumab, IL-10 gene expression increased in CD4 + Th ly and CD19 + B ly and decreased slightly in CD8 + Tc ly at 3-month follow-up, while TGF-b gene expression increased in all leucocyte subsets of adaptive immunity.
Regulatory cytokine gene expressions in cells of innate immunity in patients with RA responding to adalimumab and in the nonresponding patient IL-10 gene expression tended to be significantly downregulated (P = 0.06), while TGF-b gene expression was slightly upregulated in CD14 + monocytes at 3-month follow-up in patients with RA responding to adalimumab.
In the non-responding patient, IL-10 and TGF-b gene expressions increased in CD14 + monocytes at 3-month follow-up of treatment. ............................................................................................................................................................... gene expression of the Th1 response cytokine IFNc at 3-month follow-up of adalimumab treatment (Fig. 2) .
In CD4
+ Th ly, fold change in MC1R, MC3R and MC5R gene expressions correlated significantly to fold change in IL-1b gene expression Fold change in MC1R, MC3R and MC5R gene expressions in CD4
+ Th ly correlated significantly to fold change in the gene expression of IL-1b at 3-month follow-up of adalimumab treatment.
Correlations between fold change in MC1-5R gene expressions in CD4 + Th ly, CD8 + Tc ly, CD19 + B ly and CD14 + monocytes and clinical parameters of disease activity There were no significant correlations between fold change in MC1-5R gene expressions and percentage decrease in CRP, DAS28 (CRP), VAS pain, VAS fatigue, VAS global, HAQ, swollen or tender joints.
Discussion
This is a systematic and unique study relating TNF-aIinduced changes in MC1-5R gene expressions to changes in gene expressions of Th1 response-, inflammatory-and regulatory cytokines in pathogenetically important leucocyte subsets in RA.
Due to growing evidence of differential expression and function of specific MCRs [8] [9] [10] , we examined the gene expression of all five MCRs in important leucocyte subsets of adaptive and innate immunity and their reaction to TNF-aI with adalimumab.
The significant decrease in MC3R gene expression, we found in CD8 + Tc ly and CD19 + B ly from patients responding to adalimumab and the increase in MC3R gene expression in the non-responding patient, shows responsiveness of MC3R gene expression to adalimumab treatment. We have previously presented expression of the MC3R gene in CD8 + Tc and CD19 + B ly [7] , yet, there are no reports pertaining to the regulation of MC3R in these lymphocyte subsets in man. In monocytes however, antiinflammatory effects of melanocortin signalling are probably primarily mediated via MC3R [8, 24] . Our results reveal a pathway to selectively modulate disease driving mechanisms, exerted by CD8 + Tc and CD19 + B ly, by the targeting of MC3R. The MC3R is distinguished by a high binding affinity to c-MSH [4, 25] and may therefore be targeted selectively with synthetic MC3R selective c-MSH analogues like [D-Trp8]-gamma-MSH [26] .
We here uncovered MC4R gene expression in CD4 + Th ly, CD8 + Tc ly, CD19 + B ly and CD14 + monocytes in man. Of immune cell subsets, MC4R gene expression has previously only been demonstrated in dendritic cells, in which melanocortin signalling dampens quintessential activities such as trafficking, antigen presentation and costimulation. Yet, whether signalling by MC4R played a specific role in the regulation of dendritic cell function was not examined [27] . Furthermore, we showed that MC4R gene expression was regulated by adalimumab in CD8 + Tc ly and CD19 + B ly, as MC4R gene expression in these ly subsets decreased significantly. Of all MCRs, MC4R has a higher affinity for b-MSH than for a-MSH [4] and may thus be targeted selectively.
Even MC2R gene expression had decreased significantly at 3-month follow-up of adalimumab treatment in CD8 + Tc and CD19 + B ly due to TNF-aI and increased in the unresponsive patient. The role of MC2R signalling in inflammatory, autoimmune diseases is unknown. The MC2R only binds ACTH. In urate crystal provoked arthritis in adrenalectomized rats, ACTH injected intraarticularly had anti-inflammatory effects. However, these effects were probably mediated via MC3R, as MC3R antagonist treatment of isolated articular monocytes inhibited the effects [8] .
MC5R gene expression decreased significantly in CD19 + B ly in responders and increased in the nonresponding patient. At present, there are no reports on the effects of selective MC5R signalling in CD19 + B ly. Promisingly however, MC5R signalling has been demonstrated to convert effector CD4 + Th ly into TGF-b secreting CD25 + CD4
+ Tregs in experimental murine uveoretinitis [9] . We found that MC5R gene expression decreased, however insignificantly, in CD4 + Th ly, upon adalimumab treatment in responders, and increased in the non-responding patient.
In our hands, MC1R gene expression increased slightly in CD4 + Th ly and decreased insignificantly in remaining leucocyte subsets in responders. We have previously demonstrated MC1R protein expression in CD8 + Tc and CD19 + B ly as well as MC1R gene expression in CD4 + Th ly, CD8 + Tc ly, CD19 + B ly and CD14 + monocytes in healthy humans [6, 7] . Others have questioned whether MC1R signalling elicits any immune modulating actions at all [8, 24] . Surprisingly however, considering the immune dampening effects of the melanocortin system, MC1R signalling in CD8 + Tc ly was recently reported to increase antitumoral immunity by increasing cytotoxicity [10] .
The differential immune effects elicited by signalling through specific MCRs depend on the role of the leucocyte subset expressing the MCR. Our results showed significant correlation between the regulation of MC1R, MC3R, MC5R and IL-1b gene expressions in CD4 + Th ly. Our results support the notion of a special role for the MC5R in CD4 + Th ly function demonstrated in an animal model of autoimmune uveoretinitis [9] . Furthermore, our findings indicate a linkage between melanocortin signalling and the disease driving Th1 response, as Il-1b may exert Th1 cytokine actions [28] .
In CD8
+ Tc ly, MC2R, MC3R and MC4R were significantly downregulated by adalimumab. Considering the mechanisms regulating MCR gene expression, our findings showed that melanocortin signalling takes place in CD8 + Tc ly. Furthermore, in CD8 + Tc ly changes in the gene expressions of MC1-5R and the Th1 response signature cytokine IFN-c correlated significantly. Recently, an important role for CD8 + Tc ly in RA has been proposed [29] , supported by the presence of CD8 + Tc ly in the synovium of early, subclinical RA [30] . IFN-c production increases in CD8 + Tc ly, during their differentiation, indicating that CD8 + Tc ly beyond cytotoxicity also can exert immune directing actions [31] . Our data present a connection between melanocortin system activation and Th1 response signalling in CD8 + Tc ly, pointing at a central disease modulating role for the melanocortin system in RA. Seen in the light of the finding that melanocortin signalling in primed CD8 + Tc ly in murine contact hypersensitivity reduced the reaction to antigen [10] , we find our results promising. Yet, further functional studies are needed to assess the relation between melanocortin and IFN-c signalling in CD8 + Tc ly in RA. In CD19 + B ly, we found significant downregulation of MC2R, MC3R, MC4R and MC5R gene expressions in ............................................................................................................................................................... patients responding to adalimumab and increase in the patient, who did not respond. Thus, MCR gene expressions in CD19
+ B ly mirrored disease activity. The existence of a responsive melanocortin system in CD19 + B ly in RA is consistent with findings in a murine lupus model, in which intravenous a-MSH resulted in less immunoglobulin and antinuclear antibody production [32] .
In CD14 + monocytes, the gene expression of all five MCRs decreased, however insignificantly, in patients responding to adalimumab. Melanocortin signalling in monocytes in models of urate crystal-induced arthritis and peritonitis is predominantly mediated by MC3R and results in a reduction in Il-1b and chemokine KC release [26] . However, we found no correlations between change in MC1-5R and IL-1b gene expressions in CD14 + monocytes. Surprisingly, there was a smaller decrease in MC1-5R gene expressions in monocytes from the patient not responding to adalimumab. The only conceivable explanation is that a rise in monocytic TGF-b synthesis had suppressed MCR gene expression, as TGF-b acts reciprocal to TNF-a in the regulation of the melanocortin system [20] .
Males respond better to TNF-aI than females, when instituted within 2 years of diagnosis [33] . The disease duration of our non-respondent male patient was half a year; however, RF and ACPA titres were high. High baseline RF predicts failure to respond to TNF-aI, while there is no consensus on the impact of high baseline ACPA [34] . The role of oestrogen in RA is controversial, postmenopausal oestrogen therapy offers slight protection [35] and pregnancy may ameliorate the disease [36] . To the best of our knowledge, there are no reports on the influence of oestrogen on TNF-aI.
There are no known constitutional differences between men and women as to the gene expressions of MC1-5R. Influence of oestrogen on MCR gene expression has not been described. However in primates, oestrogen inhibits ACTH binding to MC2R [37] . It would be of interest to consider sex hormonal interference with actions of the melanocortin system as RA is far more prevalent in females.
We conclude that MC2R, MC3R and MC4R gene expressions are regulated by the cytokine environment in CD8 + Tc ly and CD19 + B ly. The demonstrated responsiveness of MCR gene expressions to changes in cytokine environment, achieved by TNF-aI, shows functioning melanocortin signalling in these lymphocyte subsets. The significant correlations, we found, between fold change in MC1-5R and Th1 response signature cytokine IFN-c gene expressions in CD8 + Tc ly and between change in several MCRs and IL-1b gene expressions in CD4 + Th ly indicate a close relationship between the regulation of melanocortin signalling and disease driving mechanisms in RA.
We suggest that melanocortin signalling constitutes a counterbalancing, pro-resolving mechanism in active RA.
In the context of the results of animal experiments, we find our results encouraging as to the pursuit of the development of a method, involving melanocortin signalling, aiming to induce immune tolerance in RA [38] .
The number of patients in our study was limited, and it is probable that the examination of the effects of adalimumab on MC1-5R gene and protein expressions in a cytokine context in a greater number of patients would have revealed further interesting connections.
